Reading TECX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TECX free→Reading TECX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TECX free→QuarterlyIQ Insights · TECX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 23, 2026, the Board of Directors (the “Board”) of Tectonic Therapeutic, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jessica Chutter as a member of the Board and as a member of the Audit Committee of the Board (the “Audit Committee”), effective as of the date of the…
Results of Operations and Financial Condition. On February 26, 2026, Tectonic Therapeutic, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 23, 2026, the Board of Directors (the “Board”) of Tectonic Therapeutic, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), approved an increase in the size of the Board from six directors to seven directors effective as of the…
Results of Operations and Financial Condition. On November 6, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended September 30, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On August 7, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended June 30, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On May 8, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Results of Operations and Financial Condition. On March 20, 2025, Tectonic Therapeutic, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Entry into a Material Definitive Agreement. Securities Purchase Agreement On February 3, 2025, Tectonic Therapeutic, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”). The Purchase Agreement provides that, subject to the satisfaction of customary closing conditions, the Purchasers will purchase an aggregate of 3,689,465 shares (the “Shares”) of common stock, $0.0001 par value per share (“Common Sto…
Regulation FD Disclosure. On February 3, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by reference herein. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The inf…
Based in part upon the representations of the Purchasers in the Purchase Agreement, the offering and sale of the Shares will be made in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), and corresponding provisions of state securities or “blue sky” laws. The Shares have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.